Cha-Mei Tang: A Leader in Innovative Cancer Diagnostics and Screening Technology

Celebrating Dr. Cha-Mei Tang's Groundbreaking Contributions to Cancer Diagnostics

In a significant recognition of excellence, Dr. Cha-Mei Tang has been named a Pinnacle Professional Member of the Inner Circle, celebrating her extraordinary contributions to cancer diagnostics and cancer screening. Her pioneering work has fundamentally transformed how cancer is detected and monitored, making a profound impact on patient care.

A Trailblazer in Cancer Research

With over fifteen years dedicated to enhancing cancer diagnostic technologies, Dr. Tang has made remarkable strides in revolutionizing the ways we understand and approach cancer care. Under her leadership at Creatv MicroTech, Dr. Tang developed the LifeTracDx® blood test—a cutting-edge diagnostic tool that provides critical insights into various types of cancer through the analysis of circulating tumor cells (CTCs).

Innovative Technology at Work

Creatv MicroTech emerged from a vision in 2010, initially focused on creating microfabrication technologies. The breakthrough came with the development of a sophisticated microfilter designed to isolate CTCs from the bloodstream of cancer patients. From the outset, Dr. Tang and her team identified a distinct group of cells—cancer-associated macrophage-like cells (CAMLs)—previously overlooked in cancer research. Their comprehensive analysis revealed that CAMLs serve as powerful biomarkers for cancer diagnosis. Unlike conventional methods, CAMLs are found in all cancer types and stages but are absent in healthy individuals, underscoring their diagnostic significance.

The Role of LifeTracDx®

The LifeTracDx® blood test not only allows for real-time prognosis but also predicts treatment responses within approximately 30 days of the first dose. It distinguishes itself by providing companion diagnostics without the need for tissue samples, making it an invaluable tool for oncologists. Furthermore, it can detect cancer recurrence and minimal residual disease (MRD), as well as deliver high-quality tumor DNA for genetic sequencing—a crucial element in personalized cancer treatment strategies.

Dr. Tang's Academic and Professional Journey

Dr. Tang’s foundation in electrical engineering and computer science was established through her education at the Massachusetts Institute of Technology (MIT), where she earned her Doctorate, Master's, and Bachelor's degrees. Her early research focused on relativistic electron beams at the U.S. Naval Research Laboratory, which laid the groundwork for her eventual foray into oncology.

Recognized as a leader in her field, Dr. Tang is an esteemed member of several professional organizations, including the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Her research has not only advanced scientific knowledge but also garnered numerous accolades, such as the WISE Award for Most Outstanding Woman Scientist in Government and the RD 100 Award from RD Magazine.

Looking to the Future

As Dr. Tang continues her work at Creatv, her focus shifts toward collaborating with pharmaceutical companies to improve the understanding of cancer drug efficacy. The company is also actively pursuing CLIA certification to conduct LifeTracDx® tests in their New Jersey laboratory, alongside applications for FDA approvals, making strides towards broader commercialization.

Dr. Tang's unwavering dedication reflects her vision of an innovative future in cancer detection, emphasizing earlier detection and more effective treatments. Her contributions are saving lives and redefining cancer diagnostics, giving hope to patients and families battling this formidable disease.

For further media inquiries, please contact Katherine Green at 516-825-5634 or [email protected]